The modified thioflavin-T derivative displayed a good binding affinity for preformed synthetic Aβ40 aggregates in solution (Ki=15±5 nM) and showed selective plaque labeling on postmortem AD brain sections.
Among these molecules, a total of 1310 and 1482 compounds having good binding affinity for BACE-1 and AChE, respectively, were identified using HTVS.
A related study has shown that paxil (CHEMBL490), one of the 5-HT reuptake inhibitors, exhibited good binding affinity for ADRB.
In IAH, the presence of 12 heavy atoms and a high potential energy of 50.33 kcal/mol suggested that this ligand molecule has a good binding affinity for human ApoE4.
To overcome these drawbacks, previous studies have used heparin for the controlled and sustained release of BMP-2 because heparin is well known to have not only good binding affinities for various growth factors but also the ability to regulate the release of growth factors [ 27– 35, 35– 35].
Noticeably, cyclopentyl-tetrazole (9a) demonstrated good binding affinity and selectivity for CB1 receptor (IC50 = 11.6 nM and CB2/CB1 = 366).
Noticeably, N4-((2S,3S -3- 3-bromophenyl -4- 4-chlorophenyl butan-2-yl -N6-butylpyrimidine-4,6-diamine (13b) demonstrated good binding affinity and decent selectivity for CB1 receptor (IC50 = 16.3 nM, CB2S,3S -3- 3-bromophenyl -4- 4-chlorophenyl butan-2-yl -N6-butylpyrimidine-4,6-diamine
Noticeably, 2- 5- 4-bromophenyl -1- 2,4-dichlorophenyl -4- 5-methyl-1,3,4-thiadiazol-2-yl -1H-pyrazol-3-yl -5- 1- trifluoromethyl cyclopropyl -1,3,4-oxadiazole (16l) demonstrated good binding affinity and decent selectivity for rCB1 receptor (IC50 = 1.72- 5- 4-bromophenyl -1- 2,4-dichlorophenyl -4- 5-methyl-1,3,4-thiadiazol-2-yl -1H-pyrazol-3-yl -5- 1- trifluoromethyl cyclopropyl -1,3,4-oxadiazole
The cooperativity between the bisquinoline and pyrrole oligoamide moieties for good binding affinity to G-quadruplex was proven by synthesizing 2 and 3 lacking a quinoline ring and pyrrole amide, respectively, and both show much reduce affinity to G-quadruplex.
Cyclic peptides combine several favorable properties such as good binding affinity, target selectivity and low toxicity that make them an attractive modality for the development of therapeutics.
